Ursodeoxycholic Acid IP 300mg

Ursomist 300 Tablet is a trusted gastroenterology medicine manufactured by Amista Labs, formulated with Ursodeoxycholic Acid IP 300 mg. It is widely prescribed for the management of gallstone-related disorders, chronic liver diseases, and bile flow abnormalities. Ursodeoxycholic Acid (UDCA) is a naturally occurring bile acid that plays a vital role in improving liver health and maintaining normal bile composition.

Composition

Each film-coated tablet contains:

• Ursodeoxycholic Acid IP 300 mg

Mechanism of Action: The Science of Ursodeoxycholic Acid

The core component of Ursomist 300 is Ursodeoxycholic Acid, a hydrophilic (water-loving) bile acid that naturally occurs in the human body in small quantities. Its therapeutic value lies in its ability to modify the composition of bile and protect liver cells.

1. Cholesterol Desaturation: Gallstones are often formed when bile becomes supersaturated with cholesterol. Ursomist-300 works by reducing the hepatic synthesis and secretion of cholesterol. It essentially lowers the cholesterol saturation index of bile, allowing cholesterol-rich stones to gradually dissolve over time without surgical intervention.

2. Cytoprotection: In chronic liver diseases, toxic hydrophobic bile acids can build up and damage liver cells (hepatocytes). Ursomist-300 displaces these toxic acids, replacing them with non-toxic UDCA. This cytoprotective effect reduces inflammation, stabilizes cell membranes, and prevents liver cell apoptosis (cell death).

3. Choleretic Effect: The medication promotes the secretion of bile, helping to flush out toxic bile acids and prevent cholestasis (stagnation of bile), which can otherwise lead to significant liver damage.

Key Therapeutic Indications and Usage

As detailed in the product profile, Ursomist 300 is indicated for a range of specific medical conditions:

• Dissolution of Gallstones: It is highly effective for patients with small, non-calcified (radiolucent) gallstones who wish to avoid cholecystectomy (gallbladder removal surgery) or for whom surgery is considered too high-risk.

• Management of Primary Biliary Cholangitis (PBC): PBC is an autoimmune disease that slowly destroys bile ducts. Ursomist-300 is the standard of care for this condition, proven to slow disease progression, improve liver biochemistry, and extend transplant-free survival rates.

• Liver Function Improvement: It is widely prescribed to improve liver function tests (LFTs) in various chronic liver disorders, including Cystic Fibrosis-related liver disease and Non-Alcoholic Fatty Liver Disease (NAFLD).

• Treatment of Bile Reflux Gastritis: This painful condition occurs when bile backs up into the stomach. Ursomist-300 helps alleviate the symptoms by altering the bile composition, making it less irritating to the stomach lining.

Packaging and Quality Assurance

Amista Labs delivers Ursomist 300 in premium Alu-Alu packaging. This type of packaging provides the highest level of protection against environmental factors such as humidity, light, and oxygen, ensuring the chemical stability of the Ursodeoxycholic Acid throughout its shelf life. The product is supplied in a 10x1x10 configuration (10 strips of 10 tablets each), which is ideal for the extended treatment plans often required for liver therapies.